Characterization of clonogenic multiple myeloma cells.

By W. Matsui, C. Huff, Qiuju Wang, M. Malehorn, J. Barber, Y. Tanhehco, B. Smith, C. Civin, Richard J. Jones. Blood, 2004

840 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Cancer stem cells: an old idea--a paradigm shift. (2006, background): “have shown that myeloma stem cells are resistant to many therapies being used to treat myeloma including chemotherapy and the proteosome inhibitor Velcade (35, 57).”
Cancer stem cells in nervous system tumors (2004, background): “In hematologic malignancies such as leukemia (Blair et al., 1997; Bonnet and Dick, 1997) and multiple myeloma (Matsui et al., 2004), and in solid tumors such as breast cancer (Al-Hajj et al., 2003), rare cells were isolated with a remarkable potential for self-renewal, and these cells alone were…”
Targeting cancer stem cell pathways for cancer therapy (2020, background): “13 CSCs expand in a symmetrical splitting manner to excessively increase cell growth, ultimately leading to tumor formation. 14 CSCs isolated from original tumor tissue that were transplanted into severe combined immunodeficiency disease (SCID) mice then formed new tumors.”
Cancer stem cells: models and concepts. (2007, methodology): “The CSC model is also being extended to lymphoid tumors, such as multiple myeloma, where it is becoming apparent that a minority subpopulation of CD138neg cells is preferentially endowed with in vitro clonogenic and in vivo engraftment capacity (68).”